Is It Possible to Have Home E-Monitoring of Pulmonary Function in Our Patients with Duchenne Muscular Dystrophy in the COVID-19 Pandemic?-A One Center Pilot Study.

AioCare COVID-19 Duchenne muscular dystrophy digital health e-monitoring of pulmonary function home monitoring home monitoring pulmonary function pulmonary function test rare diseases spirometry

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
26 08 2021
Historique:
received: 30 07 2021
revised: 19 08 2021
accepted: 24 08 2021
entrez: 10 9 2021
pubmed: 11 9 2021
medline: 15 9 2021
Statut: epublish

Résumé

Duchenne muscular dystrophy (DMD) is the most common, progressive, irreversible muscular dystrophy. Pulmonary function is crucial for duration of life in this disease. Currently, the European Respiratory Society is focused on digital health, seeking innovations that will be realistic for digital respiratory medicine to support professionals and patients during the COVID-19 pandemic. The aim of this study was to investigate whether it is possible to monitor pulmonary function at home using an individual electronic spirometry system in boys with Duchenne muscular dystrophy. In this observational, prospective study, conducted from March 2021 to June 2021, twenty boys with DMD (aged 8-16) were enrolled. The patients were recruited from the Rare Disease Centre, University Clinical Centre, of Gdańsk, Poland. Medical history and anthropometric data were collected, and spirometry (Jaeger, Germany) was performed in all patients at the start of the study. Each patient received an electronic individual spirometer (AioCare) and was asked to perform spirometry on their own every day, morning and evening, at home for a period of 4 weeks. The number of measurements, correctness of performing measurements, forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and peak expiratory flow (PEF) were evaluated. Finally, 14 out of 20 boys enrolled in the study with a mean age of 12.5 years (7 non-ambulatory) applied and received a home spirometer (AioCare). A total of 283 measurements were performed by all patients at home for 4 weeks. Half of the patients were able to perform measurements correctly. There were no significant differences between mean values of FVC, FE1, PEF between home and hospital spirometry ( Home electronic monitoring of pulmonary function in patients with DMD is possible to implement in daily routines at home. This protocol should be introduced as early as possible in patients 7-8 years old with good, preserved lung function. Patients accept this form of medical care but require more education about the benefits of e-monitoring. There is a need to implement a system to remind patients of the use of electronic medical devices at home, e.g., via SMS (short message service).

Sections du résumé

BACKGROUND
Duchenne muscular dystrophy (DMD) is the most common, progressive, irreversible muscular dystrophy. Pulmonary function is crucial for duration of life in this disease. Currently, the European Respiratory Society is focused on digital health, seeking innovations that will be realistic for digital respiratory medicine to support professionals and patients during the COVID-19 pandemic.
AIMS
The aim of this study was to investigate whether it is possible to monitor pulmonary function at home using an individual electronic spirometry system in boys with Duchenne muscular dystrophy.
MATERIALS AND METHODS
In this observational, prospective study, conducted from March 2021 to June 2021, twenty boys with DMD (aged 8-16) were enrolled. The patients were recruited from the Rare Disease Centre, University Clinical Centre, of Gdańsk, Poland. Medical history and anthropometric data were collected, and spirometry (Jaeger, Germany) was performed in all patients at the start of the study. Each patient received an electronic individual spirometer (AioCare) and was asked to perform spirometry on their own every day, morning and evening, at home for a period of 4 weeks. The number of measurements, correctness of performing measurements, forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and peak expiratory flow (PEF) were evaluated.
RESULTS
Finally, 14 out of 20 boys enrolled in the study with a mean age of 12.5 years (7 non-ambulatory) applied and received a home spirometer (AioCare). A total of 283 measurements were performed by all patients at home for 4 weeks. Half of the patients were able to perform measurements correctly. There were no significant differences between mean values of FVC, FE1, PEF between home and hospital spirometry (
CONCLUSION
Home electronic monitoring of pulmonary function in patients with DMD is possible to implement in daily routines at home. This protocol should be introduced as early as possible in patients 7-8 years old with good, preserved lung function. Patients accept this form of medical care but require more education about the benefits of e-monitoring. There is a need to implement a system to remind patients of the use of electronic medical devices at home, e.g., via SMS (short message service).

Identifiants

pubmed: 34501557
pii: ijerph18178967
doi: 10.3390/ijerph18178967
pmc: PMC8430665
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medical University of Gdańsk, Poland
ID : ST 544

Références

Lancet Neurol. 2018 Mar;17(3):251-267
pubmed: 29395989
J Chronic Dis. 1960 Aug;12:273-90
pubmed: 13842210
Eur Respir J. 2018 Feb 7;51(2):
pubmed: 29437939
Medicina (Kaunas). 2020 Aug 24;56(9):
pubmed: 32846887
Lancet Neurol. 2018 Apr;17(4):347-361
pubmed: 29395990
Eur Respir J. 2005 Jul;26(1):153-61
pubmed: 15994402
Int J Environ Res Public Health. 2021 Jun 08;18(12):
pubmed: 34200985
Muscle Nerve. 1981 May-Jun;4(3):186-97
pubmed: 7017401
Am J Respir Crit Care Med. 2020 Aug 15;202(4):P13-P14
pubmed: 32795140
Pediatr Pulmonol. 2005 May;39(5):457-60
pubmed: 15765540
Muscle Nerve. 1981 Mar-Apr;4(2):155-64
pubmed: 7207506
Muscle Nerve. 2020 Jul;62(1):41-45
pubmed: 32329920
Am J Respir Crit Care Med. 2001 Dec 15;164(12):2191-4
pubmed: 11751186
ERJ Open Res. 2020 Jan 20;6(1):
pubmed: 31984208
J Clin Med. 2021 May 28;10(11):
pubmed: 34071258
Respir Med. 2021 Aug;184:106472
pubmed: 34049155
J Asthma. 2021 Apr;58(4):505-511
pubmed: 31877056
Adv Respir Med. 2020;88(6):640-650
pubmed: 33393664
Am J Respir Crit Care Med. 2004 Aug 15;170(4):456-65
pubmed: 15302625
J Neuromuscul Dis. 2018;5(4):419-430
pubmed: 30282375
Am J Respir Crit Care Med. 2015 Dec 1;192(11):1373-86
pubmed: 26623686

Auteurs

Eliza Wasilewska (E)

Department of Allergology and Pulmonology, Medical University of Gdańsk, 80-210 Gdańsk, Poland.

Agnieszka Sobierajska-Rek (A)

Department of Rehabilitation Medicine, Medical University of Gdansk, 80-210 Gdańsk, Poland.

Sylwia Małgorzewicz (S)

Department of Clinical Nutrition, Medical University of Gdansk, 80-210 Gdańsk, Poland.

Mateusz Soliński (M)

Faculty of Physics, Warsaw University of Technology, 00-661 Warszawa, Poland.

Dominika Szalewska (D)

Department of Rehabilitation Medicine, Medical University of Gdansk, 80-210 Gdańsk, Poland.

Ewa Jassem (E)

Department of Allergology and Pulmonology, Medical University of Gdańsk, 80-210 Gdańsk, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH